US Patent

US10912814 — Combination formulation of three antiviral compounds

Formulation · Assigned to Gilead Pharmasset LLC · Expires 2037-06-01 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions containing velpatasvir, sofosbuvir, and voxilaprevir, as well as methods of using these compositions.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number: US10912814
Jurisdiction: US
Classification: Formulation
Expires: 2037-06-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.